Biotech Values

[ghmm]

BI IPF

I would be interested in the full paper if anyone reads and comments. InterMune had stated that the drop out rate was fairly high (I believe in the 30% range). With GI side effects prominant and Pirfenidone also having GI side effects I somehow doubt an elderly population would tolerate the combination. With IPF too there is still a high risk they can succeed in Phase 3. For what its worth ITMN was down ~7.5%. I don't currently have a position but this is not one of my major concerns should I take one in the future.

http://www.nejm.org/doi/full/10.1056/NEJMoa1103690